Clinical Trials Logo

Stress Disorders, Post-Traumatic clinical trials

View clinical trials related to Stress Disorders, Post-Traumatic.

Filter by:

NCT ID: NCT02486705 Completed - Clinical trials for Stress Disorders, Post-Traumatic

Evaluation of PTSD Family Coach, a Mobile Phone App for Family Members of Individuals With PTSD

Start date: January 2015
Phase: Phase 1
Study type: Interventional

The proposed pilot study is designed to test the feasibility, acceptability, and potential effectiveness of a mobile phone application (app) developed by the VA National Center for PTSD (VA NCPTSD) for use by family members of those with Posttraumatic Stress Disorder (PTSD). The primary objective of the proposed study is to assess whether family members of veterans with PTSD find the PTSD Family Coach app to be satisfactory and feasible to use. Secondary objectives are to determine if use of the app increases family members' self-efficacy and their ability to manage their own life stress, which may in part be the result of living with someone who has PTSD.

NCT ID: NCT02469259 Completed - Alcoholism Clinical Trials

The Effects of Oxytocin on Startle Hyperreactivity in Patients With AUD and PTSD

POP
Start date: February 2016
Phase: Early Phase 1
Study type: Interventional

This study will investigate the effects of oxytocin on alcohol-related behaviors, social abilities, and physiological startle responses in healthy individuals and patients with posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) using a randomized, placebo-controlled, dose-tiered, between-subject study design. Specifically, the investigators will determine if intranasal administration of a single dose of the pro-social neuropeptide oxytocin decreases alcohol-related approach bias and cravings, enhances social abilities, and decreases physiological hyperactivity. The investigators will also determine the optimal dose to achieve these effects and will explore psychosocial predictors of responses to oxytocin. The proposed work has the potential to yield a novel pharmacological treatment for AUD and PTSD, both leading causes of disability in the US Military for which currently available treatments are inadequate.

NCT ID: NCT02461732 Completed - Clinical trials for Posttraumatic Stress Disorder

Trial of a Novel Cognitive-Behavioral Treatment for Posttraumatic Stress and Substance Dependence

Start date: August 2014
Phase: N/A
Study type: Interventional

The purpose of the study is to determine whether a novel integrated cognitive-behavioral treatment for posttraumatic stress disorder (PTSD) and substance dependence (i.e., Treatment for Integrated Posttraumatic Stress and Substance use; TIPSS) is more effective than cognitive-behavioral treatment for substance dependence alone with regard to PTSD symptoms and substance use quantity and frequency.

NCT ID: NCT02459340 Completed - Clinical trials for Dissociative Disorder Not Otherwise Specified (DDNOS)

Emotional and Cognitive Self-regulation, an EEG Study

ECSR
Start date: June 2015
Phase: N/A
Study type: Interventional

The main goal of the proposed project is to assess treatment-induced changes of electrophysiological and psychophysiological correlates of the capacity to regulate emotion, executive functions, and clinical measures in individuals with complex posttraumatic stress disorder and dissociative disorders in a naturalistic inpatient setting.

NCT ID: NCT02450617 Completed - Clinical trials for Posttraumatic Stress Disorder

Stabilizing Group Treatment of Complex Trauma: A Randomized Controlled Trial

STAB
Start date: June 2014
Phase: N/A
Study type: Interventional

The research project outlined in this proposal aims to investigate the effectiveness of stabilizing group treatment as an add-on to conventional treatment, for patients with Post Traumatic Stress Disorder (PTSD) or dissociative disorders after childhood abuse. The investigators also aim to study psychophysiological markers associated with complex trauma and treatment, mechanisms of change involved in treatment, and which patient characteristics that predict positive outcome.

NCT ID: NCT02442843 Completed - Clinical trials for Posttraumatic Stress Disorder (PTSD)

Non Invasive Brain Stimulation for PTSD

Start date: May 2015
Phase: Early Phase 1
Study type: Interventional

This study is designed to identify changes in the brain that underlie symptoms of combat-related PTSD using brain imaging (fMRI). Then, the investigators will administer mild electrical stimulation to the side of the head (using a method called tDCS) in an attempt to reduce the symptoms of PTSD.

NCT ID: NCT02400736 Completed - Clinical trials for Major Depressive Disorder

Supported Employment in Patient Aligned Care Teams

Start date: August 3, 2015
Phase: N/A
Study type: Interventional

In response to the Rehabilitation Research and Development (RR&D) Deployment Health Research, this study addresses the delivery of an evidenced-based vocational rehabilitation, specifically Individual Placement and Support (IPS), for Veterans who are facing unemployment and mental illness as they try to recovery and re-establish civilian life. This study provides the requisite evidence needed to guide the Veterans Health Administration (VHA) as to whether to expand the target population for IPS to Veterans with any mental disorder, delivered directly within the primary care setting (i.e. Patient Aligned Care Team; PACT). Such modifications in VHA practice could substantially improve Veteran vocational rehabilitation access and outcomes, moving a significantly greater number of disabled Veterans back to full and productive lives in the community.

NCT ID: NCT02397889 Completed - Clinical trials for Posttraumatic Stress Disorder (PTSD)

Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)

Start date: May 18, 2015
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to study new ways to treat post-traumatic stress disorder (PTSD). Current treatments for PTSD do not work for everyone and it can take time to determine whether a person responds to a chosen treatment. The purpose of this study is to see whether ketamine, when given repeatedly intravenously can produce a quick and persistent improvement in PTSD symptoms. At higher doses, ketamine has been used for many years as an anesthetic for medical procedures, and at lower doses may be an effective treatment in patients with major depression and PTSD. Ketamine given for PTSD is investigational, which means that the FDA has not yet approved the drug for treating this condition. In this study, the effects of ketamine will be compared to those of midazolam. Midazolam has similar acute anesthetic effects compared to ketamine but has not been shown to treat or alleviate any symptoms of PTSD. This makes midazolam an appropriate substance to gauge whether ketamine can treat or alleviate PTSD symptoms thereby acting as what we call an active control.

NCT ID: NCT02382848 Completed - Clinical trials for Stress Disorders, Post-Traumatic

Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD

Start date: July 2015
Phase: N/A
Study type: Interventional

This research is being done to find out how effective Prazosin is in the treatment of bulimic patients experiencing distressing nightmares using subjective and objective measures.

NCT ID: NCT02377089 Completed - Clinical trials for Post-Traumatic Stress Disorder

Neuromodulation for Post-Traumatic Stress Disorder

Start date: May 2014
Phase: N/A
Study type: Interventional

The investigators propose to use a clinical trial to test Trigeminal Nerve Stimulation (TNS) to examine the efficacy of TNS as a new treatment for Post Traumatic Stress Disorder (PTSD) in veterans. Recruitment will take place at the PTSD Outpatient Clinic at the Veterans Affair Greater Los Angeles (VA GLA). Study participants will be asked to complete, at most, 9 assessments/questionnaires regarding their PTSD symptoms and quality of life, use the TNS device every night for 8 hours, log their use of the device, and attend weekly visits to monitor safety and complete assessments. Each subject will be asked to attend 8 visits over the course of 8 weeks. Subjects who receives the sham-controlled treatment will have an additional follow-up phone visit 4 weeks after the week 8 endpoint to examine symptom improvements. Enrollment and subject-related procedures are projected to take approximately 36 months. Preparations for clinical trial, clinical trial/study procedures and data analysis will occupy a 6 month period, a 36 month period, and a 6 month period, respectively. The duration of this project is approximately 4 years.